RT Journal Article
SR Electronic
T1 Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018
JF BMJ Open Diabetes Research & Care
JO BMJ Open Diab Res Care
FD American Diabetes Association
SP e001279
DO 10.1136/bmjdrc-2020-001279
VO 8
IS 1
A1 Clemens Engler
A1 Marco Leo
A1 Bernhard Pfeifer
A1 Martin Juchum
A1 Di Chen-Koenig
A1 Karin Poelzl
A1 Hans Schoenherr
A1 David Vill
A1 Juliana Oberdanner
A1 Egon Eisendle
A1 Klaus Middeldorf
A1 Bernhard Heindl
A1 Hannes Gaenzer
A1 Gerald Bode
A1 Karl Kirchmeyr
A1 Guenther Ladner
A1 Lisa Rieger
A1 Ursula Koellensperger
A1 Andrea Schwaiger
A1 Florian Stoeckl
A1 Guenther Zangerl
A1 Monika Lechleitner
A1 Irmgard Delmarko
A1 Wilhelm Oberaigner
A1 Clemens Rissbacher
A1 Herbert Tilg
A1 Christoph Ebenbichler
YR 2020
UL http://drc.bmj.com/content/8/1/e001279.abstract
AB Introduction Prescription patterns of antidiabetic drugs in the period from 2012 to 2018 were investigated based on the Diabetes Registry Tyrol. To validate the findings, we compared the numbers with trends of different national registries conducted in a comparable period of time.Research design and methods Medication data, prescription patterns, age groups, antidiabetic therapies and quality parameters (hemoglobin A1c, body mass index, complications) of 10 875 patients with type 2 diabetes from 2012 to 2018 were retrospectively assessed and descriptively analyzed. The changes were assessed using a time series analysis with linear regression and prescription trends were plotted over time.Results Sodium/glucose cotransporter 2 inhibitors (SGLT-2i) showed a significant increase in prescription from 2012 to 2018 (p<0.001), as well as metformin (p=0.002), gliptins (p=0.013) and glucagon-like peptide-1 agonists (GLP-1a) (p=0.017). Significant reduction in sulfonylurea prescriptions (p<0.001) was observed. Metformin was the most frequently prescribed antidiabetic drug (51.3%), followed by insulin/analogs (34.6%), gliptins (28.2%), SGLT-2i (11.7%), sulfonylurea (9.1%), glitazones (3.7%), GLP-1a (2.8%) and glucosidase inhibitors (0.4%).Conclusions In this long-term, real-world study on prescription changes in the Diabetes Registry Tyrol, we observed significant increase in SGLT-2i, metformin, gliptins and GLP-1a prescriptions. In contrast prescriptions for sulfonylureas declined significantly. Changes were consistent over the years 2012–2018. Changes in prescription patterns occurred even before the publication of international and national guidelines. Thus, physicians change their prescription practice not only based on published guidelines, but even earlier on publication of cardiovascular outcome trials.